Status: Recruiting
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.
Participants needed: 31
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: LIN YANGUpdated: Dec 2, 2024Locations: 1
Eligibility criteria
Patients with histopathological confirmed gastric/GEJ adenocarcinoma. [+14]
Histopathological types other than adenocarcinoma include squamous cell carcinom... [+25]